Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 6/20 | 0.35 |
| ▸ | CTSE | P14091 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838248 | 0.93 | CYP3A4 (0.41) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL3266288 | 0.93 | CYP3A4 (0.41) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL19372571 | 0.92 | CYP3A4 (0.42) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL13034951 | 0.92 | CYP3A4 (0.42) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL15047596 | 0.92 | CYP3A4 (0.43) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL1687443 | 0.92 | CYP3A4 (0.43) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL20684299 | 0.92 | CYP3A4 (0.43) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL19490727 | 0.92 | CYP3A4 (0.42) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL2734904 | 0.92 | CYP3A4 (0.42) | CYP3A4SSTR2RENFOLH1TTR | |
| SCHEMBL12571933 | 0.91 | CYP3A4 (0.40) | CYP3A4SSTR2RENFOLH1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409287-B9 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2021-07-21 | — | — | EP | disclosed |